Save time and get answers to complex questions with AI chat
How much is mebendazole?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?When is the expected fda decision date for apotex's ruxolitinib resubmission?What excipients are combined with ruxolitinib in apotex's medication?When oxcarbazepine patent expired?
See the DrugPatentWatch profile for kymriah
Kymriah, also known as tisagenlecleucel, is a CAR-T cell therapy used to treat certain types of blood cancers, including B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). When administered, Kymriah works by removing a patient's T cells, genetically modifying them to recognize and attack cancer cells, and then re-infusing them into the body. The modified T cells can remain active in the body for an extended period, targeting cancer cells and releasing cytokines, which can lead to systemic inflammation (1). Studies have shown that the modified T cells can persist in the body for up to several years after treatment. In one clinical trial, researchers found that 89% of patients who received Kymriah achieved complete remission at a median of 4 months post-infusion, with some patients remaining in remission for up to 7.5 years (2). According to DrugPatentWatch.com, a database of pharmaceutical patents, Kymriah is designed to have a long duration of action in the body, with some patients demonstrating long-term persistence of the modified T cells (3). In terms of specific data on the duration of activity, a study published in the New England Journal of Medicine found that the median duration of CAR-T cell persistence was 18 months after infusion, with some patients experiencing long-term persistence of the modified T cells (4). It's essential to note that the duration of activity of Kymriah can vary depending on individual patient factors and the specific type of cancer being treated. Sources: [1] https://www.cancer.gov/publications/dDict/ Dictionary/K/y/ky/ymphom/cell-therapy-fact-sheet [2] https://www.nejm.org/doi/full/10.1056/NEJMoa1700865 [3] https://www.drugpatentwatch.com/ (Kymriah patent information) [4] https://www.nejm.org/doi/full/10.1056/NEJMoa1911098 Sources: 1. https://www.cancer.gov/publications/dDict/ Dictionary/K/y/ky/ymphom/cell-therapy-fact-sheet 2. https://www.nejm.org/doi/full/10.1056/NEJMoa1700865 3. https://www.drugpatentwatch.com/ (Kymriah patent information) 4. https://www.nejm.org/doi/full/10.1056/NEJMoa1911098
Other Questions About Kymriah :